TD Cowen Sticks With United Therapeutics as Top Pick, Citing Pipeline Momentum
TD Cowen reaffirmed United Therapeutics as a top pick and left its Buy rating and $675 price target unchanged following an investor meeting where company executives outlined multiple growth drivers, including late-stage data for Tyvaso in fibrotic lung disease, an upcoming NDA for ralinepag, and ongoing xenotransplantation work. Management also rei…